|
ICGND's Operating Income Growth by Quarter and Year
Icagen,'s Operating Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
ICGND Operating Income (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
-2.69
|
-1.35
|
-0.15
|
III Quarter |
September |
-2.01
|
-1.17
|
-1.20
|
-1.07
|
II Quarter |
June |
-2.55
|
-1.57
|
-1.64
|
-1.03
|
I Quarter |
March |
-1.75
|
-3.07
|
-0.66
|
-0.96
|
FY |
|
-6.31
|
-8.50
|
-4.85
|
-3.21
|
ICGND Operating Income third quarter 2019 Y/Y Growth Comment |
Icagen, Inc. in the third quarter 2019 recorded Operating Loss of $ -2.01 millions.
According to the results reported in the third quarter 2019, Icagen, Inc. achieved the best Operating Income growth in Medical Laboratories industry. While Icagen, Inc.' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2019.
Explain Operating Income growth
|
ICGND Operating Income ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
- |
- |
- |
III Quarter |
September |
- |
- |
- |
- |
II Quarter |
June |
- |
- |
- |
- |
I Quarter |
March |
- |
- |
- |
- |
FY |
|
- |
- |
- |
- |
ICGND Operating Income (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
- |
- |
- |
III Quarter |
September |
- |
- |
- |
- |
II Quarter |
June |
- |
- |
- |
- |
I Quarter |
March |
- |
- |
- |
- |
FY (Year on Year) |
|
- |
- |
- |
- |
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Operating Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Icagen,'s Q/Q Operating Income Growth
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
ICGND's III. Quarter Q/Q Operating Income Comment |
Even if Icagen, Inc. in the III. Quarter 2019 showed Operating Loss of $ -2.01 millions, management point out, that this are slight up side in contrast to the -2.55 millions in the second quarter.
Within Medical Laboratories industry Icagen, Inc. achieved highest sequential Operating Income growth. While Icagen,'s Operating Income growth quarter on quarter, overall rank is . |
|
|
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
ICGND's III. Quarter Q/Q Operating Income Comment |
Despite the fact, that Icagen, Inc. in the III. Quarter 2019 revealed Operating Loss of $ -2.01 millions, some analyst point out, that those numbers are improvement relative to the -2.55 millions in the second quarter.
Within Medical Laboratories industry Icagen, Inc. achieved highest sequential Operating Income growth. While Icagen,'s Operating Income growth quarter on quarter, overall rank is . |
|
Icagen,'s 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Operating Income 12 Months Ending |
$ -9.00 |
$ -8.16 |
$ -7.18 |
$ -8.50 |
$ -7.17 |
Y / Y Operating Income Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Operating Income Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Operating Income Change (TTM) |
- |
- |
- |
- |
- |
Seq. Operating Income Growth (TTM) Overall
Ranking |
# |
# |
# |
# |
# |
Cumulative Operating Income growth
Comment |
Icagen, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Sep 30 2019 period. The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -8.16 millions in TTM ending quarter Jun 30 2019 and $ -7.19541 millions from the TTM period ending Sep 30 2018.
Icagen, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|
Cumulative Operating Income growth
Comment |
Icagen, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Sep 30 2019 period. The results are worsening as the cumulative Operating Loss is inflating from $ -8.16 millions in the twelve months ending a quarter before and $ -7.19541 millions for the twelve months ending in the quarter Sep 30 2018.
Icagen, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|